Merck leans on a Moderna cancer vaccine to replace its biggest drug

Merck (MRK) is spending $65 billion over five years on deals and betting on a personalized cancer vaccine built with Moderna. The goal is to fill the hole when its top seller, Keytruda, loses US patent protection. Halozyme's lawsuits over the drug's injectable form add risk. John Hickenlooper holds the stock.

Sources

Merck Bets on Moderna Cancer Vaccine and a $65 Billion Deal Spree to Soften the Keytruda Patent Cliff as Halozyme Fights Its Injection
The whole story · updated
R
Reuters
·
Pennsylvania secures $4 billion in investments, governor says
CN
CNBC
·
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in